Literature DB >> 35799061

Treatment for giant congenital nevi moves a step closer.

Joanna Pozniak1,2, Jean-Christophe Marine3,4.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35799061      PMCID： PMC9437037          DOI： 10.1038/s41422-022-00691-1

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   46.297


× No keyword cloud information.
  11 in total

1.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

2.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.

Authors:  Jürgen Bauer; John A Curtin; Dan Pinkel; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2006-08-03       Impact factor: 8.551

3.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

4.  Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.

Authors:  Marcus Bosenberg; Viswanathan Muthusamy; David P Curley; Zhenxiong Wang; Cara Hobbs; Betsy Nelson; Cristina Nogueira; James W Horner; Ronald Depinho; Lynda Chin
Journal:  Genesis       Date:  2006-05       Impact factor: 2.487

5.  Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.

Authors:  Julien Ackermann; Manon Frutschi; Kostas Kaloulis; Thomas McKee; Andreas Trumpp; Friedrich Beermann
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

6.  Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.

Authors:  Pushkar A Phadke; Dinesh Rakheja; Long P Le; Maria Angelica Selim; Payal Kapur; Amy Davis; Martin C Mihm; Mai P Hoang
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

7.  Topical therapy for regression and melanoma prevention of congenital giant nevi.

Authors:  Yeon Sook Choi; Tal H Erlich; Max von Franque; Inbal Rachmin; Jessica L Flesher; Erik B Schiferle; Yi Zhang; Marcello Pereira da Silva; Alva Jiang; Allison S Dobry; Mack Su; Sharon Germana; Sebastian Lacher; Orly Freund; Ezra Feder; Jose L Cortez; Suyeon Ryu; Tamar Babila Propp; Yedidyah Leo Samuels; Labib R Zakka; Marjan Azin; Christin E Burd; Norman E Sharpless; X Shirley Liu; Clifford Meyer; William Gerald Austen; Branko Bojovic; Curtis L Cetrulo; Martin C Mihm; Dave S Hoon; Shadmehr Demehri; Elena B Hawryluk; David E Fisher
Journal:  Cell       Date:  2022-05-12       Impact factor: 66.850

8.  Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling.

Authors:  Jeffrey S Pawlikowski; Claire Brock; Sheau-Chiann Chen; Lara Al-Olabi; Colin Nixon; Fiona McGregor; Simon Paine; Estelle Chanudet; Wendy Lambie; William M Holmes; James M Mullin; Ann Richmond; Hong Wu; Karen Blyth; Ayala King; Veronica A Kinsler; Peter D Adams
Journal:  J Invest Dermatol       Date:  2015-07-16       Impact factor: 8.551

9.  Haptenation: chemical reactivity and protein binding.

Authors:  Itai Chipinda; Justin M Hettick; Paul D Siegel
Journal:  J Allergy (Cairo)       Date:  2011-06-30

10.  Melanoma arising in a Giant congenital melanocytic nevus: two case reports.

Authors:  Tatiana S Belysheva; Yana V Vishnevskaya; Tatiana V Nasedkina; Marina A Emelyanova; Ivan S Abramov; Kristina V Orlova; Ludmila N Lubchenko; Igor A Utyashev; Marina B Doroshenko; Lev V Demidov; Mamed D Aliev
Journal:  Diagn Pathol       Date:  2019-02-19       Impact factor: 2.644
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.